- Home
- BTBD vs GNPX Comparison
BTBD vs GNPX Comparison
Compare BTBD & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTBD
- GNPX
- Stock Information
- Founded
- BTBD 1987
- GNPX 2009
- Country
- BTBD United States
- GNPX United States
- Employees
- BTBD N/A
- GNPX N/A
- Industry
- BTBD Restaurants
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- BTBD Consumer Discretionary
- GNPX Health Care
- Exchange
- BTBD Nasdaq
- GNPX Nasdaq
- Market Cap
- BTBD 11.3M
- GNPX 10.8M
- IPO Year
- BTBD 2021
- GNPX 2018
- Fundamental
- Price
- BTBD $1.76
- GNPX $4.70
- Analyst Decision
- BTBD
- GNPX
- Analyst Count
- BTBD 0
- GNPX 0
- Target Price
- BTBD N/A
- GNPX N/A
- AVG Volume (30 Days)
- BTBD 171.2K
- GNPX 1.7M
- Earning Date
- BTBD 11-12-2025
- GNPX 11-14-2025
- Dividend Yield
- BTBD N/A
- GNPX N/A
- EPS Growth
- BTBD N/A
- GNPX N/A
- EPS
- BTBD N/A
- GNPX N/A
- Revenue
- BTBD $14,533,449.00
- GNPX N/A
- Revenue This Year
- BTBD N/A
- GNPX N/A
- Revenue Next Year
- BTBD N/A
- GNPX N/A
- P/E Ratio
- BTBD N/A
- GNPX N/A
- Revenue Growth
- BTBD 1.58
- GNPX N/A
- 52 Week Low
- BTBD $1.00
- GNPX $4.64
- 52 Week High
- BTBD $5.60
- GNPX $117.50
- Technical
- Relative Strength Index (RSI)
- BTBD 46.73
- GNPX 52.76
- Support Level
- BTBD $1.74
- GNPX $7.71
- Resistance Level
- BTBD $2.10
- GNPX $9.89
- Average True Range (ATR)
- BTBD 0.15
- GNPX 1.25
- MACD
- BTBD -0.00
- GNPX -0.21
- Stochastic Oscillator
- BTBD 18.37
- GNPX 34.90
About BTBD BT Brands Inc.
BT Brands Inc operates and owns a fast-food restaurant called Burger Time. The company also operates in Minnesota as a franchisee of Dairy Queen. It offers a variety of burgers and other affordably priced foods such as chicken sandwiches, pulled pork sandwiches, chicken chunks, side dishes, and soft drinks.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.